Actimab-A is a humanized anti-CD33 antibody conjugated to Actinium-225 (Ac-225). With its potent alpha-particle payload ...

In March 2025, Akeso initiated an open-label, Phase Ib/II study involving patients diagnosed with acute myeloid leukemia (AML ...

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad ...

General and administrative (G&A) expenses for the fourth quarter of 2024 were $24.1 million, compared to $14.2 million for the fourth quarter of 2023. G&A expenses for the full year 2024 were $77.1 ...

However, these advances are not uniform across the world. In the case of patients with acute myeloid leukaemia (AML), an aggressive form of blood cancer, these advances only reach a miniscule ...

CHICAGO, ILLINOIS / ACCESS Newswire / February 17, 2025 / The American Society for Transplantation and Cellular Therapy ® (ASTCT ®) is pleased to announce David L. Porter, MD, as the Society's ...

allowing a reduced Phase 3 trial size for Annamycin with Cytarabine also known as AnnAraC in treating R/R AML patients. The global "MIRACLE" trial will span the US, Europe, and the Middle East.

Annamycin's approval in AML alone would bring the potential to ... in Part A of the trial to receive high dose cytarabine (HiDAC) combined with either placebo, 190 mg/m2 of Annamycin, or 230 ...

The MIRACLE Phase 3 study utilizes an adaptive design whereby the first 75 to 90 subjects will be randomized in Part A of the trial to receive high-dose cytarabine (HiDAC) combined with either ...